about
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionQuantitative modeling of GRK-mediated beta2AR regulationThe interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro.Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Vilanterol trifenatate for the treatment of COPD.Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.A one-week dose-ranging study of inhaled salmeterol in children with asthma.'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterolLong-acting beta 2-agonists and their role in asthma management.Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients.Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.Evidence showing that beta-adrenoceptor subtype responsible for the relaxation induced by isoprenaline is principally beta 2 but not beta 1 in guinea-pig tracheal smooth muscle.Budesonide/salmeterol in fixed-dose combination for the treatment of asthma.Use and safety of long-acting β2-agonists for pediatric asthma
P2860
Q24595639-EF8BB338-0E4E-4C0A-BA85-723AFEE369F2Q28472427-372BB71F-F45E-4224-A964-060BA3AEB9E6Q34793535-7BC490D8-DA95-4D5E-8FFB-21396DDC2A2FQ35545362-BF6A746D-1A21-41C5-B25A-591A128076A4Q38824916-A50C584B-7F32-439B-BA71-41B621B9E358Q38856871-4CF6B985-3A8B-4902-A9E1-EC022971E1BAQ39459568-B043710A-515F-4D51-9026-5A38EDDB656CQ39786582-0F4DE17D-F874-4014-B083-402580A678BDQ39826205-C945B960-44DE-455E-9195-5FEC561BF0B8Q40244779-D08AD72E-9B33-4A45-83B5-A7E42CAD48EBQ41846220-FA0E843A-C2B8-4F6B-8C2C-42659B5C8EF7Q41852598-C054AC8A-0DF9-4AB1-8E1A-7F820643AB22Q42513817-DA657169-380E-41A5-A8A5-F39F39A480C7Q42552724-0B9B4F1E-DD0B-4DD6-B1CE-88946DFCE778Q43584756-58198E4A-8179-4E15-ABA5-DAB658BDB349Q44186973-86C4778F-A8BE-46AE-BF16-8ABD2E8561D7Q45085952-FEBADA2A-7072-469E-A272-0FE0C6FDF59FQ51602950-B5AA9E0F-66ED-49B4-931B-4BC23CE70171Q57821604-6A6FC616-AC39-46DE-9415-D727FD8F27ED
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
The pharmacology of salmeterol.
@ast
The pharmacology of salmeterol.
@en
The pharmacology of salmeterol.
@nl
type
label
The pharmacology of salmeterol.
@ast
The pharmacology of salmeterol.
@en
The pharmacology of salmeterol.
@nl
prefLabel
The pharmacology of salmeterol.
@ast
The pharmacology of salmeterol.
@en
The pharmacology of salmeterol.
@nl
P2093
P1433
P1476
The pharmacology of salmeterol.
@en
P2093
Butchers PR
Coleman RA
P304
P356
10.1016/0024-3205(93)90728-L
P407
P577
1993-01-01T00:00:00Z